Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Elicio Therapeutics, Inc.’s ELTX share price has surged by 5.57%, which has investors questioning if this is right time to ...

We previously introduced the concept of 'oncogene addiction' to explain how some cancers that contain multiple genetic, epigenetic, and chromosomal abnormalities are dependent on or 'addicted' to ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Oncogene aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research. We propagate work that challenges standard conjecture and ...

Boundless Bio Inc. ( ($BOLD) ) has released its Q4 earnings. Here is a breakdown of the information Boundless Bio Inc. presented to its investors.

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...

Oncogene permanent activation in a single targeted cell of zebrafish together with a reprogramming factor transient activation is sufficient to induce the malignant transformation of the cell and ...

Elicio Therapeutics, Inc.’s ELTX share price has dipped by 19.64%, which has investors questioning if this is right time to buy.

Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on ...